Nowe metody terapii cukrzycy – insulina wziewna
Piśmiennictwo
1. Gaensslen M. Ueber Inhalation von Insulin. Klin
Wochenschr 1925; 4: 71-72
2. Patton J., Bukar J., Eldon M. Clinical
Pharmacokinetics and Pharmacdynamics of Inhaled Insulin. Clin. Pharmacokinet.
2004; 43 (12): 781-801
3. Skyler J., Cefalu W., Kourides I. i wsp.
Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised
proof-of-concept study. Lancet. 2001; 357: 331-335
4. Heise T., Rave K., Bott S., i wsp.
Time-action profile of an inhaled insulin preparation in comparison to insulin
lisipro and regular insulin [abstract]. Diabetes 2000 ; 49 Suppl. 1:A 10
5. Brunner G., Balent B., Ellmerer M. i wsp.
Dose-response relation of liquid aerosol inhaled insulin in type I diabetic
patients. Diabetologia. 2001; 44(3): 305-308
6. Ellis SL, Gemperline KA, Garg SK. Review of Phase 2 Studies Utilizing the AIR® Particle Technology in the
delivery of Human Insulin Inhalation Powder Versus Subcutaneous Regular or
Lispro Insulin in Subjects with Type 1 or Type 2 Diabetes. Diabetes Technol
Ther. 2007; 9(s1): S48-56
7. De Galan BE, Simsek S, Tack CJ, Heine RJ.
Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth
J Med. 2006; 64(9): 319-325
8. Richardson
PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther. 2007;
9(s1) :S65-72
9. Exubera package insert. New York , NY:
Pfizer Labs;2006 May
10. Patton JS, Bukar J, Nagarajan S. Inhaled
insulin. Adv Drug Deliv Rev. 1999; 35(2-3): 235-247
11. Barnett AH, Dreyer M, Lange P,
Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the
efficacy and safety profile of inhaled human insulin (Exubera) with metformin
as adjunctive therapy ina patients with type 2 diabetes poorly controlled on a
sulfonylurea. Diabetes Care. 2006; 29(6): 1282-1287
12. Newhouse M. Tennis anyone?The lungs as a
new court for systemic therapy.CMAJ 1999;161:1287-1288
13. Cappelleri JC, Cefalu WT, Rosenstock J,
Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison
between an inhaled insulin regimen and subcutaneous insulin regimen. Clin
Ther.2002; 24(4); 552-564
14. Guntur VP, Dhand R. Inhaled insulin:
extending the horizons of inhalation therapy. Respir Care. 2007; 52(7): 911-922
15. Henry R., Mudaliar S., Howland III W. i
wsp. Inhaled insulin using the AERx insulin diabetes management system in
healthy and asthmatic subjects. Diabetes Care. 2003; 26(3): 764-769
16. Rave K, de la Pena A, Tibaldi FS, Zhang
L, Silverman B, Hausmann M, Heinemann L, Muchmore DB
17. AIR inhaled insulin in subjects with
chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety,
and tolerability.Diabetes Care. 2007 Jul;30(7):1777-82
18. Mudaliar S, Henry RR. Inhaled insulin in
patients with asthma and chronic obstructive pulmonary disease
19. Diabetes Technol Ther. 2007 Jun;9 Suppl
1:S83-92.
20. Gern JE, Stone CK, Nakano M, Muchmore DB,
de la Pena A,
Park S, Suri A, Tibaldi F, Soon D, Busse WW. Effect of Upper Respiratory Tract
Infection on AIR Inhaled Insulin Pharmacokinetics and Glucodynamics in Healthy
Subjects. Clin Pharmacol Ther. 2007 Jul 11; [Epub ahead of print]
21. Kohler D. Aerosois for systemic treatment.
Lung 1990;168(suppl): 677-684
22. Departament of Health and Human Services
Food and Drug Administration Center
for Drug Evaluation and Research Endocrinologic and Metabolic Drugs Advisory
Committee. www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4169T1.pdf Transcript of the meeting of Thursday,September 8,2005
23. Himmelmann A., Jendle J., Mellen A.,
Petersen A., Dahl U., Wollmer P. The impact of smoking on inhaled insulin.
Diabetes Care. 2003; 26(3): 677-682
24. Facchini F., Hollenbeck C., Jeppesen J,
Chen YDI, Reaven G. Insulin resistance and cigarette smoking. Lancet. 1992;
339: 1128–1130
25. Attvall S., Fowelin J., Lager I., Von Schenk
H., Smith U. Smoking induces insulin resistance: a potential link with the
insulin resistance syndrome. J Intern Med. 1993; 233: 327–332
26. Targher G., Alberiche M., Zenere M.,
Bonadonna R., Muggeo M., Bonora E. Cigarette smoking and insulin resistance in
patients with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab.
1997; 82: 3619–3624.
27. Becker RH, Sha S, Frick AD, Fountaine RJ.
The effect of smoking cessation and subsequent resumption on absorption of
inhaled insulin.Diabetes Care. 2006 Feb;29(2):277-82.
28. Quattrin T., Belanger A., Bohannon N., Schwartz
S. Exubera Phase III Study Group.
Efficacy and safety of inhaled insulin
(Exubera) compared with subcutaneous insulin therapy in patients with type 1
diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care.
2004; 27(11): 2622-2627
29. Royle P, Waugh N, McAuley L, McIntyre L,
Thomas S. inhaled insulin in diabetes mellitus. Cochrane database Syst Rev.
2004; (3): CD003890
30. Ceglia L, Lau J, Pittas AG. Meta-analysis:
efficacy and safety of inhaled insulin therapy in adults with diabetes
mellitus.Ann Intern Med. 2006 Nov 7;145(9):665-75.
31. Barnett AH, Bellary S. Inhaled human
insulin (Exubera): clinical profile and patient considerations Vasc Health Risk
Manag. 2007;3(1):83-91.
32. Fineberg S., Kawabata T., Finco-Kent D.,
Liu C., Krasner A. Antibody Response to Inhaled Insulin in Patients with Type 1
or Type 2 Diabetes. J Clin Endocrinol Metab.
33. 2005; 90(6): 3287-3294
34. Leslie CC, McCormick-Shannon K, Robinson
PC, Mason RJ. Stimulation of DNA synthesis in cultured ratn alveolar type II
cells.Exp Lung Res 1985;8:5666
35. Iida K, Suzuki H, Sone H, et al. Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via
phosphatidylinositol-3-kinase-dependent pathway. Arterioscler Thromb Vasc Biol
2002;22:380-386
36. Chailler P., Briere N. Insulin alters cell
proliferation during the early development of rodent kidney. Cell Biol Int Rep.
1991; 15(10): 955-963
37. Menard D., Corriveau L., Beaulieu J.
Insulin modulates cellular proliferation in developing human jejunum and colon.
Biol Neonate. 1999; 75(3): 143-151
